Figure S2. Effect of FLAG-Tagged TECPR2 on the Mutation
Expressions of each alleles of N-terminus or C-terminus FLAG tagged TECPR2 and their effects of proteasome inhibition with MG132 and Lactacystin. (A) Immunoblotting with anti-FLAG monoclonal antibody for HEK293 transfectants of N-terminus or C-terminus FLAG tagged TECPR2. (-),empty vector; GAPDH, loading control. (B) Immunoblotting with anti-FLAG monoclonal antibody for HeLa transfectants of N-terminus or C-terminus FLAG tagged TECPR2. Data supports the results in Figure 3D ,E with the same notations.
Plasmid preparation: First half and second half of cDNAs encoding human TECPR2 were amplified from the human kidney cell line HEK-293 with RNeasy plus (QIAGEN, Santa Clarita, CA), High Capacity cDNA Reverse Transcription Kit (Applied Biosystems, Foster city, CA), PfuUltra II Fusion HS DNA Polymerase (Agilent Technologies, Palo Alto, CA), with primer sets shown in Table S3 . cDNAs were subcloned into the pCR-Blunt II-TOPO vector (Invitrogen-Life Technologies, Carlsbad, CA, USA) and subjected to sequence analysis. Using pCR-Blunt II-TECPR2-2nd-3416T, 3416delT of TECPR2 was made by PCR-directed mutagenesis using Phusion HF DNA polymerase and specific T4-phosphorylated primer set, and amplicon was self-ligated using T4 DNA ligase (Promega, Madison, WI), and subjected to sequence analysis. Using pCR-blunt II-TECPR2-1st, N-terminus FLAG was made by two-step PCR-directed mutagenesis using Phusion HF DNA polymerase and specific T4-phosphorylated primer sets, self-ligated using T4 DNA ligase, and subjected to sequence analysis. Using pCR-Blunt II-TECPR2-2nd-3416T or pCR-Blunt II-TECPR2-2nd-3416delT, C-terminus FLAG was made by the same way. cDNA encoding 1st half of human TECPR2 which was subcloned into pCR-blunt II vectors that included the second half of TECPR2, using the Sal I sites from pCR-blunt II vectors which include first half of TECPR2. cDNAs encoding full length N-terminus or C-terminus FLAG-tagged human TECPR2 which contain each of the alleles were subcloned into pcDNA3.1(+) vector (Invitrogen-Life Technologies) using the KpnI and XhoI sites and subjected to sequence analysis.
Inhibiting the proteasome pathway: Empty pcDNA3.1 (+) vector, pcDNA3.1(+)-TECPR2-3416T-N-FLAG, pcDNA3.1(+)-TECPR2-3416delT-N-FLAG, pcDNA3.1(+)-TECPR2-3416T-C-FLAG or pcDNA3.1(+)-TECPR2-3416delT-C-FLAG were transfected into monkey kidney cell line COS-7, human kidney cell line HEK-293 and human epithelial cell line HeLa by lipofection using Lipofectamine 2000 (Invitrogen-Life Technologies). After 32h, transfectants were incubated with 
N-terminus FLAG C-terminus FLAG
20µM of MG132 (Sigma Aldrich) and 20µM of Lactacystin (Sigma Aldrich). After 48h of transfection, the cells were lysed with Nupage LDS sample buffer (Invitrogen) with DL-Dithiothreitol (Sigma Aldrich) and the lysates were subjected to SDS-PAGE gel and transferred to a polyvinylidene difluoride membrane (Millipore, Billerica, MA).
Figure S3. Effect of Mutation on Autophagy Markers in Skin Fibroblasts
Full data supporting the results of the three biological replicates in Figure 4B with the same notations, using immunoblot scan quantitation and normalization by GAPDH (Exp1 and 2) or Actin (Exp 3) control. 
